MOONLAKE IMMUNOTHERAPEUTICS Earnings Per Share (Basic)
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Earnings Per Share (Basic) of -$0.84 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-10
- MOONLAKE IMMUNOTHERAPEUTICS earnings per share, basic for the quarter ending 2026-06-30 was -$0.84.
- MOONLAKE IMMUNOTHERAPEUTICS earnings per share, basic for the quarter ending 2026-03-31 was -$0.98.
- MOONLAKE IMMUNOTHERAPEUTICS earnings per share, basic for the quarter ending 2025-12-31 was -$0.92.
- MOONLAKE IMMUNOTHERAPEUTICS earnings per share, basic for the quarter ending 2025-09-30 was -$1.10.
- MOONLAKE IMMUNOTHERAPEUTICS earnings per share, basic for fiscal 2025 was -$3.53.
- MOONLAKE IMMUNOTHERAPEUTICS earnings per share, basic for fiscal 2024 was -$1.89.
- MOONLAKE IMMUNOTHERAPEUTICS earnings per share, basic for fiscal 2023 was -$0.73.
- MOONLAKE IMMUNOTHERAPEUTICS earnings per share, basic for fiscal 2022 was -$1.70.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 10 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$0.84 10-Q · filed 2026-08-10 | -$1.81 10-Q · filed 2026-08-10 | -$2.73 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$3.81 derived: net income ÷ weighted average shares · filed 2026-08-10 | |
| 2026-03-31 | -$0.98 10-Q · filed 2026-05-11 | -$1.90 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$2.99 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$3.87 derived: net income ÷ weighted average shares · filed 2026-08-10 | |
| 2025-12-31 | -$0.92 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.01 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$2.89 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$3.53 10-K · filed 2026-02-25 | |
| 2025-09-30 | -$1.10 10-Q · filed 2025-11-05 | -$1.97 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$2.61 10-Q · filed 2025-11-05 | -$3.33 derived: net income ÷ weighted average shares · filed 2026-08-10 | |
| 2025-06-30 | -$0.87 10-Q · filed 2026-08-10 | -$1.50 10-Q · filed 2026-08-10 | -$2.23 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$2.79 derived: net income ÷ weighted average shares · filed 2026-08-10 | |
| 2025-03-31 | -$0.63 10-Q · filed 2026-05-11 | -$1.35 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$1.92 derived: net income ÷ weighted average shares · filed 2026-05-11 | -$2.30 derived: net income ÷ weighted average shares · filed 2026-05-11 | |
| 2024-12-31 | -$0.72 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.29 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.67 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.89 10-K · filed 2026-02-25 | |
| 2024-09-30 | -$0.56 10-Q · filed 2025-11-05 | -$0.95 derived: net income ÷ weighted average shares · filed 2025-11-05 | -$1.17 10-Q · filed 2025-11-05 | -$1.30 derived: net income ÷ weighted average shares · filed 2026-04-21 | |
| 2024-06-30 | -$0.39 10-Q · filed 2025-08-05 | -$0.60 10-Q · filed 2025-08-05 | -$0.73 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.92 derived: net income ÷ weighted average shares · filed 2026-04-21 | |
| 2024-03-31 | -$0.22 10-Q · filed 2025-05-12 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.52 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.74 derived: net income ÷ weighted average shares · filed 2026-04-21 | |
| 2023-12-31 | -$0.12 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.30 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.52 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.73 10-K · filed 2026-02-25 | |
| 2023-09-30 | -$0.18 10-Q · filed 2024-11-07 | -$0.40 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$0.63 10-Q · filed 2024-11-07 | -$1.04 derived: net income ÷ weighted average shares · filed 2026-04-21 | |
| 2023-06-30 | -$0.23 10-Q · filed 2024-08-07 | -$0.46 10-Q · filed 2024-08-07 | -$0.89 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.16 derived: net income ÷ weighted average shares · filed 2026-04-21 | |
| 2023-03-31 | -$0.23 10-Q · filed 2024-05-07 | -$0.66 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.94 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.28 derived: net income ÷ weighted average shares · filed 2026-04-21 | |
| 2022-12-31 | -$0.43 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$0.71 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.05 derived: net income ÷ weighted average shares · filed 2026-04-21 | -$1.70 10-K · filed 2025-02-26 | |
| 2022-09-30 | -$0.27 10-Q · filed 2023-11-14 | -$0.62 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$1.27 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | -$0.34 10-Q · filed 2023-08-10 | -$1.13 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | -$3.17 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | -$6.84 10-K · filed 2023-03-20 | ||||
| 2021-09-30 | -$2.63 10-Q · filed 2022-11-14 | -$5.70 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$4.06 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | -$2.90 10-Q · filed 2022-08-12 | -$2.11 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |